Načítá se...
Personalized therapy for lung cancer: striking a moving target
Molecular targeted therapy heralded a new era for the treatment of patients with oncogene-driven advanced-stage non–small-cell lung cancer (NSCLC). Molecular testing at the time of diagnosis guides therapy selection, and targeted therapies in patients with activating mutations in EGFR, BRAF, and rea...
Uloženo v:
| Vydáno v: | JCI Insight |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6129126/ https://ncbi.nlm.nih.gov/pubmed/30089719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.120858 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|